Industry Reports
Teva to Report First Quarter 2016 Financial Results on May 9, 2016
Teva Pharmaceutical Industries Ltd  announced that it will release its first quarter 2016 financial results on Monday, May 9, 2016 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same...
Industry Reports
Teva to Report First Quarter 2016 Financial Results on May 9, 2016
Teva Pharmaceutical Industries Ltd. announced that it will release its first quarter 2016 financial results on Monday, May 9, 2016 at 7:00 a.m. ET. World pharma today/Industry Reports /- Teva will host a conference call and...
Industry Reports
Lilly To Provide Detailed Update Of Pipeline And R&D Strategy At Upcoming Investment Community Meeting
Eli Lilly and Company announced it will host a meeting for the investment community, including institutional investors, sell-side analysts, ratings agency representatives, and financial and business media. World pharma today/Industry reports/- The meeting will take place...
Industry Reports
INNATE PHARMA IN-LICENSES OREGA BIOTECH’S FIRST-IN-CLASS ANTI-CD39 CHECKPOINT INHIBITOR PROGRAM
This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune responses across a wide range of tumors; Anti-CD39 broadens Innate Pharma’s portfolio of innovative immuno-oncology...
Industry Reports
CTI BioPharma Announces $15.7 Million Registered Direct Offering
CTI BioPharma Corp. announced that it has entered into an agreement with institutional investors to purchase 10 million shares of the Company's common stock in a registered direct offering conducted without an underwriter or placement agent for gross proceeds...
Industry Reports
Seattle Genetics, BMS to evaluate Adcetris and Opdivo combination
Seattle Genetics and Bristol-Myers Squibb (BMS) have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Adcetris and Opdivo in two planned Phase I/II clinical trials. Adcetris (brentuximab vedotin) is Seattle Genetics'...
Industry Reports
Ireland’s Shire to acquire NPS Pharmaceuticals for $5.2bn
Irish drugmaker Shire has signed a merger agreement to acquire US-based NPS Pharmaceuticals for $5.2bn. As part of the deal, Shire will acquire NPS Pharma's outstanding shares for $46 per share in cash. The transaction was...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
